StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $5.14 | $4.70 | -8.56% | 0.1M |
| 05-19 | $4.60 | $5.27 | +14.57% | 0.1M |
| 05-20 | $5.15 | $5.60 | +8.74% | 0.1M |
| 05-21 | $5.48 | $5.91 | +7.85% | 0.2M |
| 05-22 | $5.93 | $5.88 | -0.84% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2015 2015-12-31 | Annual 2013 2013-12-31 | Q3 2013 2013-09-30 | Q2 2013 2013-06-30 |
|---|---|---|---|---|
Revenue | $200.00K | $0.00 | $0.00 | $0.00 |
Operating Income | $-2.65M | $-1.37M | $-1.02M | $-702.75K |
Net Income | $-2.85M | $-1.37M | $-1.02M | $-702.75K |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $597.98K | $558.04K | $873.82K | $1.14M |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $25.28K | $475.02K | $790.97K | $1.08M |
Free Cash Flow OCF − CapEx | Not available | $-1.18M | $-866.06K | $-581.62K |
Shares Outstanding | 47.88M | 41.58M | 41.58M | 41.58M |
No sell-side coverage available for LIXT yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.